Medico Intercontinental Limited has announced that its Promoter and Managing Director significantly increased his shareholding through open market transactions. The pharmaceutical company disclosed this substantial acquisition under SEBI regulations on December 26, 2025.

Transaction Overview

Mr. Samir Dilipkumar Shah, Managing Director and Promoter of Medico Intercontinental Limited, acquired additional equity shares through open market purchase, triggering disclosure requirements under SEBI substantial acquisition regulations.

Shareholding Changes

The acquisition resulted in a notable increase in Mr. Shah's shareholding percentage in the company:

Regulatory Compliance

The disclosure was made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulatory framework requires disclosure when there is a substantial change in shareholding that crosses specified thresholds.

The company's equity share capital stands at ₹10.00 crores, with the total diluted share capital remaining unchanged post-acquisition. Mr. Shah communicated the transaction details to BSE Limited, where the company's shares are listed under scrip code 539938.

Persons Acting in Concert

The disclosure identified several Persons Acting in Concert (PAC) with the acquirer, including family members and related entities. The PAC group includes Dilipkumar Bhogilal Shah, Jay Sharadkumar Shah, Dineshkumar Sevantilal Shah, Siddharth Dinesh Shah, Bhartiben Dineshbhai Shah, and Shah Dinesh Sevantilal HUF, maintaining their collective 12.68% shareholding.

Company Profile

Medico Intercontinental Limited operates in the pharmaceutical sector with its registered office at 1-5th Floor, Aditraj Arcade, Near Hetvi Tower, 100 Ft Road, Satellite, Ahmedabad-380015. The company maintains compliance with all regulatory requirements through timely disclosures of material transactions by promoters and key management personnel.

Medico Intercontinental Limited, an Ahmedabad-based pharmaceutical company, has announced its unaudited financial results for the first quarter of fiscal year 2026, showcasing remarkable growth across key financial metrics.

Standalone Performance

The company's standalone performance for Q1 FY26 demonstrated exceptional growth:

• Total income from operations surged by 345% to Rs. 3,011.32 lakhs, compared to Rs. 676.44 lakhs in the corresponding quarter of the previous year.
• Net profit after tax witnessed a substantial increase, reaching Rs. 483.50 lakhs, up from Rs. 44.42 lakhs in Q1 FY25.
• Earnings per share (EPS) grew significantly to Rs. 3.19, compared to Rs. 0.37 in the same quarter last year.

Consolidated Results

On a consolidated basis, Medico Intercontinental's performance was equally impressive:

• Total income rose by 263% to Rs. 3,330.41 lakhs, up from Rs. 916.11 lakhs in Q1 FY25.
• Net profit after tax increased to Rs. 566.84 lakhs, compared to Rs. 152.27 lakhs in the corresponding quarter.
• Consolidated EPS improved to Rs. 3.90, up from Rs. 1.27 in Q1 FY25.

Financial Highlights

The Board of Directors approved these unaudited financial results on August 14, 2025. The company's performance reflects strong growth in both standalone and consolidated operations, indicating robust business expansion and improved profitability.

Medico Intercontinental Limited, with its registered office in Ahmedabad, continues to strengthen its position in the pharmaceutical sector. The significant increase in revenue and profitability suggests effective business strategies and potentially expanded market reach.

Investors and stakeholders can access the detailed financial results on the company's website and the stock exchange websites.